PRED MILD Rx
Generic Name and Formulations:
Prednisolone acetate 0.12%; oph. susp; contains benzalkonium chloride, sulfites.
Indications for PRED MILD:
Adults and Children:
Instill 1–2 drops 2–4 times daily. During the initial 24–48hrs, the dosing frequency may be increased if needed.
Fungal, mycobacterial, viral (except herpes zoster) or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Myopia. Diabetes. Asthma. Monitor for secondary infections and intraocular pressure in prolonged use. Avoid abrupt cessation. Re-evaluate if no improvement after 2 days. Pregnancy. Nursing mothers.
May mask or exacerbate infections. Increased intraocular pressure, posterior subcapsular cataract formation, delayed wound healing, corneal perforations, optic nerve damage, defects in visual acuity and fields of vision, allergic reactions.
Mild—5mL, 10mL; Forte—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML